1. Home
  2. PAAS vs VTRS Comparison

PAAS vs VTRS Comparison

Compare PAAS & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pan American Silver Corp.

PAAS

Pan American Silver Corp.

SELL

Current Price

$43.21

Market Cap

18.8B

Sector

N/A

ML Signal

SELL

Logo Viatris Inc.

VTRS

Viatris Inc.

SELL

Current Price

$18.14

Market Cap

18.7B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
PAAS
VTRS
Founded
1994
1961
Country
Canada
United States
Employees
N/A
30000
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.8B
18.7B
IPO Year
1998
2019

Fundamental Metrics

Financial Performance
Metric
PAAS
VTRS
Price
$43.21
$18.14
Analyst Decision
Buy
Buy
Analyst Count
9
12
Target Price
★ $63.03
$19.70
AVG Volume (30 Days)
2.7M
★ 8.0M
Earning Date
11-04-2026
11-05-2026
Dividend Yield
1.62%
★ 2.75%
EPS Growth
★ N/A
N/A
EPS
N/A
★ 0.05
Revenue
N/A
★ $14,299,900,000.00
Revenue This Year
$22.64
$3.44
Revenue Next Year
$6.46
$1.68
P/E Ratio
★ $33.54
$349.40
Revenue Growth
★ N/A
N/A
52 Week Low
$33.08
$9.92
52 Week High
$69.99
$18.43

Technical Indicators

Market Signals
Indicator
PAAS
VTRS
Relative Strength Index (RSI) 38.90 63.56
Support Level $41.34 $15.94
Resistance Level $46.82 $18.30
Average True Range (ATR) 1.15 0.50
MACD -0.23 -0.01
Stochastic Oscillator 29.75 81.49

Price Performance

Historical Comparison
PAAS
VTRS

About PAAS Pan American Silver Corp.

Pan American Silver Corp is a mining company principally engaged in the operation and development of, and exploration for, silver and gold-producing properties and assets. The company's principal products are silver and gold, although it also produces and sells zinc, lead, and copper. Its operating mines comprise La Colorada, Dolores, Huaron, Morococha, Shahuindo, La Arena, Timmins West, Bell Creek, Manantial Espejo, and San Vicente mines.

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Share on Social Networks: